argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART® for the treatment of adults with gMG.
April 5, 2022
· 10 min read